Tillman Gerngross (Adagio)

A glob­al pan­dem­ic fi­as­co sets the stage for Till­man Gern­gross to in­tro­duce his biotech uni­corn to Wall Street

This morn­ing we got a bet­ter look at the num­bers Till­man Gern­gross has in mind for his pan­dem­ic play at Ada­gio Ther­a­peu­tics. And not sur­pris­ing­ly, they are big.

Gern­gross has had plen­ty of ex­pe­ri­ence judg­ing val­ue in biotech. And at a time the top mR­NA play­ers at Mod­er­na and BioN­Tech/Pfiz­er are reap­ing some vast gains from their tru­ly rev­o­lu­tion­ary new vac­cines for Covid-19, it’s clear that the Dart­mouth pro­fes­sor has been build­ing a uni­corn of his own.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.